- Under Priority Review status, the FDA has accepted Merck's (NYSE:MRK) new supplemental Biologics License Application (sBLA) for KEYTRUDA, an anti-PD-1 therapy, in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with carcinoma of the esophagus and gastroesophageal junction (GEJ).
- The PDUFA, or target action date is set to April 13, 2021.
- https://seekingalpha.com/news/3645215-fda-accepts-mercks-application-for-keytruda-chemotherapy-in-esophageal-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.